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Objective: Research in lung transplant preservation has generally focused
on free radicals and enzyme release from neutrophils, parenchymal cells,
macrophages, and endothelium. The lung has a large resident population of
mast cells that, when activated, release potent inflammatory mediators. We
hypothesized that adding an inhibitor of mast cell degranulation, lodox-
amide tromethamine (10 mmol/L), to Euro-Collins and University of
Wisconsin preservation solutions, would decrease lung preservation injury.
Methods: Rat lungs were isolated, flushed with the respective solution, and
stored at 4° C for 6 or 12 hours. The lungs were reperfused with fresh blood
and ventilated with 100% oxygen. Alveolar-arterial oxygen difference,
oxygen tension, capillary filtration coefficient, and compliance were deter-
mined. Results: After 6 hours of ischemic storage: lodoxamide trometham-
ine–enhanced Euro-Collins solution decreased alveolar-arterial oxygen
difference from 539 to 457 (p 5 0.004), increased oxygen tension from 119
to 205 mm Hg (p 5 0.006), and decreased capillary filtration coefficient
from 3.9 to 2.0 (p < 0.001); lodoxamide tromethamine–enhanced University
of Wisconsin solution decreased alveolar-arterial oxygen difference from
546 to 317 (p < 0.001), increased oxygen tension from 166 to 335 mm Hg
(p < 0.001), and decreased capillary filtration coefficient from 3.0 to 1.7
(p < 0.001). After 12 hours of ischemic storage, lodoxamide tromethamine–
enhanced Euro-Collins solution decreased alveolar-arterial oxygen differ-
ence from 588 to 485 (p < 0.001), increased oxygen tension from 100 to 161
mm Hg (p 5 0.012), decreased capillary filtration coefficient from 6.2 to 2.6
(p < 0.001), and increased compliance from 0.12 to 0.21 (p < 0.001);
lodoxamide tromethamine–enhanced University of Wisconsin solution
decreased alveolar-arterial oxygen difference from 478 to 322 (p < 0.001),
increased oxygen tension from 214 to 335 mm Hg (p < 0.001), decreased
capillary filtration constant from 4.2 to 2.0 (p < 0.001), and increased
compliance from 0.20 to 0.25 (p < 0.001). Conclusions: Addition of lodox-
amide tromethamine to Euro-Collins or University of Wisconsin solution
results in a marked decrease in lung reperfusion injury as demonstrated by
increased oxygenation, decreased microvascular permeability, and in-
creased compliance. These results are relevant as Euro-Collins and Uni-
versity of Wisconsin solutions are the most common clinically used lung
preservation solutions. This study also highlights the deleterious role of
resident mast cells in preservation injury. (J Thorac Cardiovasc Surg 1998;
115:631-7)
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Research in pulmonary transplant preservationhas generally focused on understanding and
preventing ischemia-reperfusion injury. The delete-
rious effects of oxygen-derived free radical forma-
tion, neutrophil infiltration, and cellular protease
release have been extensively investigated and are
considered to be the primary mediators of ischemia-
reperfusion injury. Although lung preservation tech-
niques have benefited from information regarding
these pathophysiologic mechanisms, the problem of
reperfusion injury, experimentally and clinically,
continues to result in unpredictable graft function,
and other mechanisms of injury have been suggest-
ed.1 Mast cells can be activated by ischemia and
reperfusion,2, 3 and they release thromboxanes,
platelet-activating factor, histamine, prostaglandins,
and leukotrienes. These substances cause smooth
muscle contraction, increased vascular permeability,
and neutrophil chemotaxis, all of which may ad-
versely affect lung function after transplantation.
Human lungs have an inherent population of mast
cells (approximately 500 to 4000/mm3), which reside
in the perivascular, peribronchiolar, and bronchoal-
veolar spaces.
Lodoxamide tromethamine (LT) is a derivative of
the anti-allergy drug cromolyn sodium (INN: cro-
moglicic acid) and inhibits mast cell degranulation
in vitro and in vivo.4 The drug was originally devel-
oped for prophylaxis of mast cell–mediated asthma.
It has the additional effects of being a hydroxyl
radical scavenger5 and an inhibitor of xanthine
oxidase6 and neutrophil chemotaxis.7 On the basis
of these properties, LT has been used experimen-
tally to decrease ischemia-reperfusion injury in car-
diac8 and spinal cord9 models. Previous studies have
used high-dose LT to prevent pulmonary ischemia-
reperfusion injury by inhibiting xanthine oxidase.10
In an isolated, crystalloid-perfused rat heart model,
we had previously demonstrated that a lower dose of
LT could reduce cardiac mast cell degranulation
and reduce myocardial dysfunction after hypoxia
and reoxygenation.11 On the basis of the signifi-
cantly higher density of mast cells in the lungs, we
hypothesized that adding a mast cell–inhibiting dose
of LT to the most commonly used lung preservation
solutions, Euro-Collins (EC) and University of Wis-
consin (UW) solutions, would decrease ischemia-
reperfusion injury and improve pulmonary preser-
vation after prolonged ischemic storage. We
evaluated this hypothesis in an isolated, blood-
perfused rat lung model in which physiologic param-
eters, as well as experimental measurements of
capillary permeability, could be assessed.
Methods
All animals received humane care according to the
“Principles of Laboratory Animal Care,” formulated by
the National Society for Medical Research, and the
“Guide for the Care and Use of Laboratory Animals,”
prepared by the National Academy of Sciences and pub-
lished by the National Institutes of Health (NIH publica-
tion No. 86-23, revised 1985).
Donor procedures
Lungs. Male Lewis rats (250 to 350 gm) were anesthe-
tized (sodium pentobarbital, 50 mg/kg, intraperitoneally)
and tracheostomized with a stopcocked 14-gauge angio-
catheter. A rodent ventilator (Harvard Apparatus Com-
pany, S. Natick, Mass.) was used to maintain normal
respiration (respiratory rate, 50/min; tidal volume, 10
ml/kg; positive end-expiratory pressure, 2 cm H2O; room
air). A median sternotomy and thymectomy were per-
formed, the thoracic organs exposed, and the inferior
pulmonary ligaments divided. Heparin (1000 U) was then
injected via the inferior vena cava. The inferior and
superior venae cavae were ligated and divided, and the
apex of the heart was amputated. The lungs were flushed
via the main pulmonary artery with cold preservation
solution (4° C; 50 ml/kg) from a height of 30 cm. On
completion of the flush, the tracheal catheter was oc-
cluded to maintain lung inflation, and the donor heart and
lungs were removed en bloc, suspended from a support
rod in the esophagus, and secured to the tracheal catheter
and stopcock with 3-0 ligatures. The heart-lung block was
immediately submerged in the corresponding preserva-
tion solution–filled plastic container, covered with plastic
wrap, and maintained at 4° C for the remainder of the
ischemic storage period.
Blood. Male Lewis rats were placed under surgical
anesthesia as previously described. A sternotomy and
laparotomy were performed and heparin (1000 U) was
injected via the inferior vena cava. Blood was obtained via
a subdiaphragmatic inferior vena caval puncture and the
animal was put to death with pentobarbital (100 mg/kg,
intraperitoneally).
Reperfusion and monitoring
Reperfusion. After the designated storage period, the
pulmonary artery and the left atrium were cannulated
with 14-gauge angiocatheters via the right and left ventri-
cles, respectively, and the catheters were secured with 8-0
ligatures. The cannulated block was then suspended from
a force transducer via the esophagus, placed in a humid-
ified, temperature-controlled (37° C) chamber, and venti-
lated with 100% oxygen according to the previously
described ventilatory parameters. Reperfusion was initi-
ated by connecting the pulmonary artery cannula to a
reservoir containing the previously obtained fresh synge-
neic venous blood, suspended from a height that gener-
ated 15 mm Hg of pressure. The left atrial cannula was
then connected to a separate reservoir, and the heights of
the two reservoirs were adjusted to produce an isogravi-
metric state (state of no net weight gain) at which the
lungs were maintained for 5 minutes. At the end of the
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5-minute isogravimetric equilibration period, the capillary
pressure was increased 10 mm Hg by raising the heights of
the pulmonary artery and left atrial reservoirs, and the
resulting pressure was maintained for 15 minutes.
Monitoring. Throughout the reperfusion period, speci-
men weight (FT 03 force-displacement transducer, Grass
Instruments, Inc., Quincy, Mass.), inflow pressure and
outflow pressure (DTX model T4812 AD-R pressure
transducer, Viggo-Spectramed, Oxnard, Calif.), tracheal
pressure (Validyne DP 45-24 differential pressure trans-
ducer, Validyne Engineering Corp., Northridge, Calif.),
and tidal volume (Fleisch No. 2 pneumotachograph, Whit-
taker Medical Manufacturing, Richmond, Va.; Validyne
DP 45-14 pressure transducer) were measured. All data
were transmitted to an AST Bravo IBM-compatible com-
puter via a Validyne CD 280 and MC 1-3 carrier demod-
ulator and a Dash 16 A/D converter (Validyne), and
processed and displayed by a customized version of Mi-
crosoft Visual Basic Pro software (Microsoft Corporation,
Redmond, Wash.). With an analysis and computation
time of 10 seconds, six recordings per 1 minute of data
flow were performed.
Experimental protocol. Isolated lungs were flushed
with either modified EC solution (Euro-Collins solution,
Baxter Healthcare Products, Deerfield, Ill.; modified with
2.5 ml 50% magnesium sulfate and 50 ml 50% dextrose
per liter) or UW solution (Viaspan, DuPont Merck Phar-
maceutical, Wilmington, Del., with 40 U insulin and 16 mg
dexamethasone per liter) and stored in the same solution
for 6 or 12 hours. Control lungs were flushed and stored
using standard solution, and experimental lungs were
flushed and stored using solution with 10 mmol/L of LT.
At each storage time there were two experimental and two
control groups consisting of six lungs each: standard EC,
standard UW, EC1LT (EC1L), and UW1LT (UW1L).
Data analysis
Determination of the capillary filtration coefficient (Kf).
The calculation of the capillary filtration coefficient (Kf)
has been previously described in detail.12 In brief, Kf was
assessed by increasing pulmonary capillary pressure 10
mm Hg from an initial isogravimetric state and measuring
the rate of weight gain caused by edema formation. Three
minutes were allowed before Kf measurement for com-
pletion of rapid weight gain resulting from vascular filling
and distention. The rate of slow weight gain that occurred
during minutes 3 to 8 was plotted semilogarithmically and
extrapolated back to time zero (when the capillary pres-
sure was initially raised). The time zero filtration rate was
divided by the change in capillary pressure and normal-
ized to 100 gm wet lung weight to express Kf in milliliters
per minute per millimeters of mercury per 100 gm.
Blood gas analysis. A blood sample from the left atrium
was collected at the end of the reperfusion period to
assess the gas exchange capability of the lungs. Samples
were analyzed with a Ciba Corning 288 blood gas and
electrolyte analyzer (Ciba Corning, Medfield, Mass.).
Measured values of oxygen tension (PO2) and a calculated
alveolar-arterial oxygen difference (A-aDO2) were re-
corded.
Compliance. Recorded tidal volume/airway pressure
values were measured every 10 seconds and averaged over
the 5-minute isogravimetric period to assess lung compli-
ance.
Statistics. All data were compared by one-way analysis
of variance with Student-Newman-Keuls post-test. All
data are expressed as mean 6 standard deviation.
Results
Compliance (Fig. 1). Higher compliance values
correspond with better lung function. Compliance
values were significantly higher in the UW1L and
EC1L groups than in the UW and EC groups after
12 hours of ischemic storage: EC1L (0.21 6 0.02)
versus EC (0.12 6 0.01), p , 0.001; UW1L (0.25 6
0.02) versus UW (0.20 6 0.01), p , 0.001. Compli-
ance values were significantly higher for the UW1L
group when compared with the EC1L group for
both storage times: for 6 hours, UW1L (0.23 6
0.02) versus EC1L (0.19 6 0.02), p 5 0.008; for 12
hours, UW1L (0.25 6 0.02) versus EC1L (0.21 6
0.02), p 5 0.008. Compliance values were signifi-
cantly higher for the UW group than for the EC
group at the 12-hour storage time: UW (0.20 6
0.01) versus EC (0.12 6 0.01), p , 0.001.
A-aDO2 (Fig. 2). Lower A-aDO2 values correspond
with improved gas exchange capability. At both
storage times, A-aDO2 values were significantly lower
in the UW1L and EC1L groups when compared
with the UW and EC groups: for 6 hours, EC1L
(457 6 2) versus EC (539 6 22), p 5 0.004; UW1L
Fig. 1. Compliance for all groups at 6 and 12 hours of
storage. Compliance was measured as tidal volume/airway
pressure and expressed in milliliters per centimeter of
water. The only significant comparison at the 6-hour
storage time was UW1L versus EC1L, p 5 0.008.
Significant comparisons at the 12-hour storage time were
as follows: EC1L versus EC, p , 0.001; UW1L versus
UW, p , 0.001; UW1L versus EC1L, p 5 0.008; UW
versus EC, p , 0.001.
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(317 6 36) versus UW (546 6 38), p , 0.001; for 12
hours, EC1L (485 6 46) versus EC (588 6 26), p ,
0.001; UW1L (322 6 51) versus UW (478 6 40),
p , 0.001. A-aDO2 values were significantly lower for
the UW1L group than for the EC1L group at both
storage times: for 6 hours, UW1L (317 6 36) versus
EC1L (457 6 42), p , 0.001; for 12 hours, UW1L
(322 6 51) versus EC1L (485 6 46), p , 0.001.
A-aDO2 values were significantly lower for the UW
group than for the EC group at the 12-hour storage
time: UW (478 6 40) versus EC (588 6 26), p ,
0.001.
PO2 (Fig. 3). Higher PO2 in left atrial pulmonary
outflow blood samples indicated improved oxygen-
ation ability. At both storage times PO2 values were
significantly higher for the UW1L and EC1L
groups when compared with the EC and UW
groups: for 6 hours, EC1L (205 6 51) versus EC
(119 6 23), p 5 0.006; UW1L (335 6 50) versus
UW (166 6 57), p , 0.001; for 12 hours, EC1L
(161 6 22) versus EC (100 6 35), p 5 0.012; UW1L
(335 6 49) versus UW (214 6 30), p , 0.001. PO2
values were significantly higher for the UW1L
group than for the EC1L group at both storage
times: for 6 hours, UW1L (335 6 50) versus EC1L
(205 6 51), p , 0.001; for 12 hours, UW1L (335 6
49) versus EC1L (161 6 22), p , 0.001. PO2 values
were significantly higher for the UW group than for
the EC group at the 12-hour storage time: UW
(214 6 30) versus EC (100 6 35), p , 0.001.
Kf (Fig. 4). The value of Kf for a given lung
specimen reflects the rate of edema formation
across the microvascular membranes and is a sensi-
tive experimental measurement of lung injury. De-
creased Kf values correspond to improved mem-
brane integrity with decreased capillary permeability
and decreased impairment of lung function. At both
storage times, Kf values were significantly lower for
the UW1L and EC1L groups than for the UW and
EC groups: for 6 hours, EC1L (2.0 6 0.30) versus
EC (3.9 6 0.30), p , 0.001; UW1L (1.7 6 0.30)
versus UW (3.0 6 0.40), p , 0.001; for 12 hours,
EC1L (2.6 6 0.20) versus EC (6.2 6 0.50), p ,
0.001; UW1L (2.0 6 0.40) versus UW (4.2 6 0.40),
p , 0.001. Kf values were significantly lower for the
UW1L group than for the EC1L group at the
12-hour storage time: UW1L (2.0 6 0.40) versus
EC1L (2.6 6 0.20), p 5 0.009. Kf values were
significantly lower in the UW group than in the EC
group at both storage times: for 6 hours, UW (3.0 6
0.40) versus EC (3.9 6 0.3), p , 0.001; for 12 hours,
UW (4.2 6 0.40) versus EC (6.2 6 0.50), p , 0.001.
Discussion
By evaluating the functional parameters of gas
exchange and compliance and the experimental
Fig. 2. A-aDO2 (in millimeters of mercury) for all groups
at 6 and 12 hours of storage. Significant comparisons at 6
hours of storage were as follows: EC1L versus EC, p 5
0.004; UW1L versus UW, p , 0.001; UW1L versus
EC1L, p , 0.001. Significant comparisons at 12 hours of
storage were as follows: EC1L versus EC, p , 0.001;
UW1L versus UW, p , 0.001; UW1L versus EC1L, p ,
0.001; UW versus EC, p , 0.001.
Fig. 3. PO2 in millimeters of mercury for all groups at 6
and 12 hours of storage. Significant comparisons at 6
hours of storage were as follows: EC1L versus EC, p 5
0.006; UW1L versus UW, p , 0.001; UW1L versus
EC1L, p , 0.001. Significant comparisons at 12 hours
were as follows: EC1L versus EC, p 5 0.012; UW1L
versus UW, p , 0.001; UW1L versus EC1L, p , 0.001;
UW versus EC, p , 0.001.
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measurement of the Kf, this study demonstrates that
adding LT to EC and UW preservation solutions
improves the postischemic function of cold stored
rat lungs. Edema, impaired gas exchange, and de-
creased compliance are hallmarks of ischemia-
reperfusion injury in lung transplantation and can
lead to increased postoperative morbidity and mor-
tality. Protective effects in lungs preserved in EC
and UW solution supplemented with LT were man-
ifested by decreased edema, better gas exchange
capabilities, and better compliance as quantified by
lower Kf values, higher PO2 values, lower A-aDO2
values, and increased compliance, respectively.
Mast cells are inflammatory cells that can be acti-
vated by changes in cyclic nucleotide concentration,
calcium influx, and immunoglobulin E–antibody com-
plexes.13 They have also been shown to be activated by
reperfusion in an ischemic dog lung model14 and most
recently in a syngeneic rat transplant model.2 When
activated, mast cells release a variety of vasoactive
substances that cause smooth muscle contraction, in-
creased vascular permeability, and neutrophil chemo-
taxis. The mechanism by which mast cells are activated
by reperfusion is unclear, but their potential contribu-
tion to transplant preservation injury is increasingly
apparent on the basis of recent studies.2, 3
In our study, the probable mechanism by which
LT exerted the observed protective effects was inhi-
bition of mast cell degranulation. The concentration
of LT (10 mmol/L) that was used is in the optimal
range for preventing histamine release from isolated
rat mast cells.4 This same concentration was also
shown to inhibit mast cell degranulation and prevent
reperfusion injury in our prior work in isolated rat
hearts.11 As the effects of the substances released on
mast cell degranulation are to increase vascular
permeability (edema) and bronchial smooth muscle
contraction, the decrease in these effects observed in
lungs flushed and stored using LT-enhanced solu-
tions can be attributed to the decrease in mast cell
mediator release. Resident mast cells located in the
pulmonary interstitium were the likely target of LT
action, as it was added to the preservation solution
and not to the reperfusion blood. Hydroxyl radicals,
xanthine oxidase formation, and neutrophil chemo-
taxis are known to contribute to ischemia-reperfu-
sion injury.7, 8, 15 Inasmuch as LT has been shown to
be a substrate for the hydroxyl radical5 and an
inhibitor of xanthine oxidase6 and direct neutrophil
chemotaxis,7 it could be interpreted that the ob-
served beneficial effects in this study were derived
from these alternative properties of LT. However,
because of the dose used in this study, we believe
that non-mast cell–mediated effects played a minor
role, if any, in decreasing reperfusion injury. Forty-
eight percent xanthine oxidase inhibition in vitro is
achieved at a concentration 8 times higher (80
mmol/L) than was used,6 xanthine oxidase is inhib-
ited in vivo at a concentration 100 times higher
(1000 mmol/L),10 direct neutrophil chemotaxis is
achieved in vitro at a concentration 25 times higher
(250 mmol/L),7 and hydroxyl radical scavenging is
observed at a concentration 48 times higher (480
mmol/L).5 Mast cell response to LT is biphasic; at
low doses (10 to 50 mmol/L) mediator release is
inhibited and at higher doses (50 to 500 mmol/L)
mediator release is enhanced.16 It is possible that
part of the beneficial effect afforded by LT was due
to inhibition of indirect neutrophil chemotaxis re-
sulting from the direct inhibition of mast cell de-
granulation; however, because of the low concentra-
tion of LT that was used, the majority of the protective
effects were likely a consequence of mast cell degran-
ulation inhibition. This hypothesis is also supported by
results from our work in the rat cardiac model in which
reperfusion was performed with an asanguineous crys-
talloid solution, thus eliminating circulating neutrophil
chemotaxis as a possible contributor.
The data from this study support previous find-
ings that UW is superior to EC for experimental
Fig. 4. Kf for all groups at 6 and 12 hours of storage. Kf
was normalized to 100 gm wet lung weight and expressed
in milliliters per minute per milligrams of mercury per 100
gm. Significant comparisons at 6 hours were as follows:
EC1L versus EC, p , 0.001; UW1L versus UW, p ,
0.001; UW versus EC, p , 0.001. Significant comparisons
at 12 hours were as follows: EC1L versus EC, p , 0.001;
UW1L versus UW, p , 0.001; UW1L versus EC1L, p 5
0.009; UW versus EC, p , 0.001.
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lung preservation.17, 18 The superiority of UW pres-
ervation was demonstrated by the improved func-
tion of lungs preserved with standard UW and
UW1L compared with lungs preserved with stan-
dard EC and EC1L. UW1L-preserved lungs func-
tioned better that EC1L-preserved lungs in most
end-point categories at both 6 and 12 hours. UW-
preserved lungs performed significantly better than
EC-preserved lungs in all end-point categories at 12
hours of storage. The difference at the 6-hour
storage time was represented by the significantly
lower Kf in the UW group. Kf is known to be a
sensitive indicator of changes in endothelial mem-
brane integrity19 and thus the improved protection
afforded by UW was demonstrated.
Although extrapolation from a rodent model to
clinical human lung transplantation is always prob-
lematic, this study provides evidence that inhibition
of resident mast cell degranulation decreases pul-
monary reperfusion injury. Inasmuch as the human
lung is known to contain an even greater inherent
population of mast cells than is the rat, this study has
potential clinical implications. The exact mechanism
by which mast cells are activated by reperfusion
remains unclear, however, and further study is re-
quired to fully describe their role in clinical reper-
fusion injury.
This study also indicates that EC and UW, the
two most commonly used clinical lung preservation
solutions, are not optimal because they were both
significantly improved by adding LT. In the devel-
opment of new lung preservation solutions, we
believe there may be a benefit to considering the
role of the mast cell in reperfusion injury and
incorporating mast cell stabilizing compounds into
the solutions.
R E F E R E N C E S
1. Bishop MJ, Chi EY, Su M, Cheney FW. Dimethylthiourea
does not ameliorate lung reperfusion injury in dogs or
rabbits. J Appl Physiol 1987;63:942-50.
2. Minani M, Nakahara K, Matasamura A, Mizuta T, Yoon H,
Sakaguchi M, et al. Histamine release from pulmonary mast
cells after lung transplantation in rats. J Heart Lung Trans-
plant 1995;14:505-11.
3. Buvry A, Garbarg M, Dimitriadou V, Roulleau A, Newlands
GFJ, Tavakole R, et al. Phenotypic and quantitative changes
in mast cells after syngeneic unilateral lung transplant in the
rat. Clin Sci 1996;91:319-27.
4. Johnson HG, Sheridan AQ. The characterization of lodox-
amide, a very active inhibitor of mediator release, in animal
and human models of asthma. Agents Actions 1986;3/4:
301-5.
5. Till GO, Guilds LS, Mahrougui M, Friedl HP, Trentz O,
Ward P. Role of xanthine oxidase in thermal injury of skin.
Am J Pathol 1989;135:195-202.
6. White GJ. Inhibition of oxidative enzymes by anti-allergy
drugs. Agents Actions 1981;11:503-9.
7. Veal CF Jr, Jackson RM, Brannen AL, Fulmer JD. Lodox-
amide tromethamine prevents neutrophil accumulation in
reexpansion pulmonary edema. J Card Pharmacol 1989;14:
227-32.
8. Jolly SR, Abrams GD, Romson JL, Baile MB, Lucchesi BR.
Effects of lodoxamide on ischemic reperfused myocardium.
J Cardiovasc Pharmacol 1982;4:441-8.
9. Ball TD, Lundy EF, Zelenock GB, D’Alecy LG. Effects of
lodoxamide tromethamine on paraplegia that occurs after
infrarenal aortic occlusion in the rabbit. J Vasc Surg 1987;6:
572-7.
10. Lynch MJ, Grum CM, Gallagher KP, Bolling SF, Deeb GM,
Morganroth ML. Xanthine oxidase inhibition attenuates
ischemic reperfusion lung injury. J Surg Res 1988;44:538-44.
11. Keller AM, Clancy RM, Barr ML, Marboe CC, Cannon PJ.
Acute reoxygenation injury in the isolated rat heart: role of
resident cardiac mast cells. Circ Res 1988;63:1044-52.
12. Drake R, Garr A, Taylor AE. Estimation of the filtration
coefficient of pulmonary exchange vessels. Am J Physiol
1978;234:H266-74.
13. Dvorak AM, Peters SP, Sherman ES. Mast cells. In: Massory
D, editor. Lung cell biology. New York: Marcell Dekker;
1989. p. 345-78.
14. Su M, Chi EJ, Bishop MJ, Henderson WR Jr. Lung mast cells
increase in number and degranulate during pulmonary artery
occlusion/reperfusion injury in dogs. Am Rev Respir Dis
1993;147:448-56.
15. McCord JM. Oxygen derived free radicals in postischemic
tissue injury. N Engl J Med 1985;312:159-63.
16. Johnson HG. New anti-allergy drugs—the lodoxamides.
TIPS August 1980:343-5.
17. Xiong L, Mazmanian M, Chapelier AR, Reighner J, Weiss
M, Dartevelle PG, et al. Lung preservation with Euro-
Collins, University of Wisconsin, Wallwork, and low-potassi-
um-dextran solutions. Ann Thorac Surg 1994;58:845-50.
18. Aeba R, Kennan RJ, Hardesty RL, Yousem SA, Hamamoto
I, Griffith R. University of Wisconsin solution for pulmonary
preservation in a rat transplant model. Ann Thorac Surg
1992;53:240-6.
19. Drake RE, Laine GA. Pulmonary microvascular permeability
to fluid and macromolecules. J Appl Physiol 1988;64:487-501.
Discussion
Dr. Paul F. Waters (Los Angeles, Calif.). I have a
number of questions. First, is EC or UW solution better in
this model? From your data, it appears that UW solution
is better. I notice that your UW solution contains steroid.
Do you think that has any effect on the mast cells and
maybe could account for that difference?
Dr. Barr. That is a good question, but I do not have an
answer. We just tried to imitate what we would normally
do in the clinical scenario of adding dexamethasone and
insulin just as is recommended. In terms of your observa-
tion about UW being better than EC, other groups have
shown that, too, and some of us believe that is the case
clinically. However, in every experiment that we have
done in our laboratory comparing EC and UW, either
with large animals or with small animals, UW was supe-
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rior. UW was statistically superior to unmodified EC
solution every time, independent of the issue of mast cells.
I do not know whether steroids play a big role or not.
Dr. Waters. Why did you use syngenetic blood instead
of the donor animal’s blood?
Dr. Barr. Because this is not a recirculating model,
there would be insufficient blood from the donor animal.
We used blood from another Lewis rat so that we could
eliminate the issue of an allogeneic response and just have
pure reperfusion injury.
Dr. Waters. Was the temperature of the perfused blood
controlled?
Dr. Barr. Yes, it was.
Dr. Waters. It would have been tempting to look at the
histologic features. Did you think about doing that?
Dr. Barr. In fact, we did that. The issue of how well
histologic characteristics correlate is a matter of contro-
versy in preservation research. Even though UW solution
has worked better in animal and human studies, the
histologic features of the endomyocardial biopsy speci-
men, for instance in heart preservation, look worse. We
did do electron microscopic studies on some of these
samples and could not see any differences. Laboratories in
addition to ours have not found differences in function as
it relates to histologic features. However, we did not
include this material in our report because we observed no
difference between the two groups.
Dr. Waters. My final comment is a more fundamental
question. A number of preservation solutions have been
fantastic in the rat model, but those results have not
persisted when tested in larger animals and ultimately
patients. Solutions in the Japanese work, LPD, for in-
stance, have worked well experimentally but have not
worked in human beings. Do you think that the rat is a
relevant model for lung preservation?
Dr. Barr. When I used the word validated, I actually
meant in regard to our parameters and Kf. I agree with
you completely about the relevance of studies in rats. We
do need to take this to a larger animal model, ideally
primates, before doing a study in human beings. In fact,
our next set of experiments is in primates.
Dr. Waters. Did you consider implanting the lung in this
study? Putting the lung into a rat would be more physio-
logic and perhaps change what we would observe.
Dr. Barr. We did not do that in this experiment. The
reason is that we believe very strongly in the Kf as a
measurement for detecting changes between experimental
groups. Groups that have compared UW versus EC with
an implanted graft have shown results similar to those we
just showed, but they were not able to measure the same
parameters.
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